 Aduro Biotech Inc. will cut nearly 60 of its workforce and close its European office a month after Swiss partner Novartis AG stepped away from a four-year cancer drug collaboration. The Berkeley company NASDAQ: ADRO said the restructuring would cut 51 jobs in all. The cuts are needed to align operating capital and personnel for a collaboration with Eli Lilly and Co. NYSE: LLY in cancer, autoimmune diseases and inflammatory diseases, Aduro Chairman, President and CEO Stephen Isaacs said in a statement. 